Kusurinomadoguchi (5592) FY2026 Q3 Earnings Report

Quick View

Executive Summary

FY2026 Q3 consolidated results showed strong performance with revenue of ¥89.3B (YoY +6.0%), operating income of ¥20.1B (+29.5%), ordinary income of ¥20.1B (+30.8%), and net income of ¥21.5B (+36.9%). The company demonstrated significant profit expansion outpacing revenue growth, with operating margin expanding to 22.6% and net margin reaching 24.1%. The bottom-line growth was particularly robust, accelerating at nearly six times the rate of revenue growth, driven by operational leverage and favorable tax effects. Cash position strengthened materially to ¥33.5B, up 59.2% YoY, reflecting improved liquidity. The company operates as a single-segment business providing solutions to pharmacies, medical institutions, and nursing care facilities.

Performance Drivers

Revenue grew 6.0% YoY to ¥89.3B, reflecting steady demand expansion in the pharmacy and healthcare solutions market. The company serves a single integrated market of pharmacies, medical institutions, and nursing care facilities, with growth driven by increased adoption of its solution offerings and expansion of the existing customer base. Gross profit reached ¥50.8B with a margin of 57.0%, indicating strong pricing power and a favorable service-oriented business model. SG&A expenses totaled ¥30.7B, representing 34.4% of revenue, demonstrating effective operating leverage as the ratio improved from prior periods while supporting revenue growth.

Operating income surged 29.5% to ¥20.1B, substantially outpacing revenue growth and reflecting improved operational efficiency. The operating margin expanded to 22.6%, up significantly from the prior year, driven by gross margin stability and SG&A leverage. Ordinary income increased 30.8% to ¥20.1B, closely aligned with operating income, suggesting minimal non-operating impacts. Non-operating income and expenses largely offset at ¥0.4B each, with interest expense of ¥0.1B reflecting modest debt servicing costs.

Net income jumped 36.9% to ¥21.5B, exceeding ordinary income by ¥1.4B. This unusual dynamic reflects extraordinary income of ¥0.1B and a negative effective tax rate of approximately -6.9%, indicating significant tax benefits likely from deferred tax asset recognition or tax loss carryforwards reversal. While this tax effect boosted near-term earnings, it represents a non-recurring factor that may not persist in future periods. Basic EPS reached ¥189.36, up 33.1% YoY, slightly below net income growth due to share count adjustments.

This represents a revenue up/profit up pattern with accelerated profit growth driven by operational leverage and temporary tax benefits.

Key Metrics

[Profitability] ROE of 21.7% demonstrates strong return generation, substantially exceeding the company's cost of capital. Operating margin of 22.6% reflects the high-value nature of software and solution services, with gross margin of 57.0% indicating strong pricing power in the healthcare IT market. Net profit margin reached 24.1%, elevated by favorable tax effects. [Cash Quality] Cash and deposits of ¥33.5B provide 3.35x coverage of short-term debt, indicating robust liquidity. The cash position increased 59.2% YoY, strengthening the balance sheet buffer. [Investment Efficiency] Asset turnover of 0.60 reflects the intangible asset-intensive nature of the business, with software comprising ¥39.1B or 26.3% of total assets. [Financial Health] Equity ratio of 66.6% demonstrates conservative capitalization with low leverage risk. Current ratio of 210.5% indicates strong short-term liquidity, though short-term liabilities represent 53.8% of total liabilities, warranting attention to refinancing continuity. Debt-to-equity ratio of 0.19 confirms minimal leverage, with interest-bearing debt totaling ¥18.6B against equity of ¥99.1B.

Cash Flow Analysis

Cash and deposits increased ¥12.5B YoY to ¥33.5B, representing a 59.2% expansion that significantly strengthened liquidity positioning. This substantial cash accumulation occurred alongside operating profit growth of 29.5%, suggesting strong operating cash generation supported earnings expansion. Working capital movements show accounts receivable at ¥37.9B, representing 42.4% of revenue on an annualized basis, which translates to approximately 155 days sales outstanding, indicating extended collection cycles typical of institutional healthcare customers but warranting monitoring for collection risk. Long-term borrowings increased dramatically from ¥0.6B to ¥8.6B, a ¥8.0B addition suggesting strategic financing to support growth initiatives or balance sheet optimization. Treasury stock increased to -¥4.3B from near-zero, reflecting share repurchase activity that returned capital to shareholders. Retained earnings grew ¥18.1B to ¥56.6B, with the majority of net income retained for reinvestment. The combination of strong cash accumulation, modest debt addition, and capital returns indicates balanced financial management with adequate liquidity coverage at 3.35x short-term obligations.

Earnings Quality

Ordinary income of ¥20.1B versus operating income of ¥20.1B shows negligible non-operating net contribution, indicating earnings are predominantly driven by core operations. Non-operating income and expenses each totaled ¥0.4B, effectively offsetting and contributing minimally to earnings. Interest expense of ¥0.1B represents modest financing costs relative to the debt outstanding. The primary earnings quality concern stems from the gap between ordinary income of ¥20.1B and net income of ¥21.5B, with the ¥1.4B difference driven by an effective tax rate of -6.9%. This negative tax rate reflects non-cash tax benefits, likely from deferred tax asset recognition, which enhances reported earnings but does not represent sustainable operating performance or cash generation. While extraordinary items were minimal at ¥0.1B in gains, the tax effect represents approximately 6.5% of net income and warrants classification as a non-recurring boost. The underlying operating performance remains strong, but investors should normalize for the tax benefit when assessing sustainable earning power. Absent detailed operating cash flow disclosure, the extended accounts receivable cycle of 155 days suggests potential timing differences between revenue recognition and cash collection, though the substantial cash balance growth provides assurance of fundamental cash generation quality.

Guidance Update

Full-year guidance projects revenue of ¥123.0B (+9.8% YoY), operating income of ¥24.5B (+25.4%), and ordinary income of ¥24.0B (+23.7%). Q3 cumulative progress rates stand at 72.6% for revenue, 82.2% for operating income, and 83.8% for ordinary income. Operating and ordinary income are tracking approximately 32-34 percentage points ahead of the standard 50% mid-year benchmark, indicating stronger-than-seasonal first-half performance. This front-loaded earnings profile suggests either accelerated project deliveries, seasonal business mix favoring H1, or conservative full-year guidance. Given the 82-84% progress rate through Q3, the company would need to generate only ¥4.4B in operating income in Q4 to meet guidance, compared to Q3 quarterly operating income of ¥20.1B for nine months, implying approximately ¥6.7B quarterly average. This suggests the guidance may prove conservative, though management may be anticipating typical Q4 seasonality or one-time factors. Annual dividend forecast of ¥36.00 per share implies a payout ratio of approximately 15.2% based on the EPS forecast of ¥236.79, maintaining a conservative capital distribution policy that prioritizes reinvestment and balance sheet strength.

Shareholder Returns

Annual dividend forecast of ¥36.00 represents the company's distribution plan, with interim dividend of ¥9.00 and year-end dividend expected at ¥27.00. Based on forecast EPS of ¥236.79, the payout ratio stands at 15.2%, reflecting a highly conservative dividend policy that retains the vast majority of earnings for reinvestment. This low payout ratio provides substantial headroom for dividend sustainability and potential increases, supported by strong cash generation and low leverage. The company executed share repurchases during the period, with treasury stock increasing to ¥4.3B from near-zero in the prior year, representing meaningful capital return supplementing dividends. While specific repurchase amounts are not itemized, the treasury stock increase demonstrates active shareholder return alongside dividend payments. Combined, the total return ratio incorporating both dividends and buybacks would approximate 20-25% of earnings, remaining conservative relative to the strong cash position and low leverage. The capital allocation strategy prioritizes reinvestment in growth initiatives, particularly software development and intangible assets that comprise 31% of total assets, while maintaining flexibility for opportunistic returns.

Risk Factors

Single-segment concentration in pharmacy and healthcare solutions creates customer base risk, as regulatory changes, healthcare reimbursement reforms, or technology disruption in the Japanese medical system could materially impact demand. The company's entire revenue base depends on the pharmacy, medical, and nursing care sectors, limiting diversification and exposing results to sector-specific headwinds. Software and intangible assets totaling ¥46.3B represent 31.1% of total assets, exceeding typical concentration thresholds and creating impairment risk if technology becomes obsolete, customer adoption slows, or competitive pressures intensify. A material impairment charge would directly impact equity and profitability. Accounts receivable of ¥37.9B with estimated days sales outstanding of 155 days indicates extended collection cycles that expose the company to customer credit risk and working capital pressure. If major institutional customers face financial stress or payment delays extend further, cash conversion could deteriorate materially despite strong reported earnings, particularly given the high short-term liability proportion requiring refinancing continuity.

Industry Benchmark (Reference - Proprietary Data)

[Industry Position] (Reference - Proprietary Analysis) The company demonstrates strong competitive positioning within the IT and Telecom sector serving healthcare markets. Profitability metrics substantially exceed industry norms: ROE of 21.7% compares favorably to the industry median of 8.3%, placing the company in the top quartile for return generation. Operating margin of 22.6% significantly outperforms the industry median of 8.2%, reflecting superior operational efficiency and the high-margin nature of its healthcare solution offerings. Net profit margin of 24.1% stands well above the industry median of 6.0%, though elevated by temporary tax benefits, the underlying operating margin still demonstrates premium positioning. Financial health indicators show conservative capitalization: equity ratio of 66.6% exceeds the industry median of 59.2%, indicating lower leverage risk than peers. Current ratio of 210.5% compares favorably to the industry median of 2.15x, though this is influenced by the company's minimal inventory business model. Revenue growth of 6.0% trails the industry median of 10.4%, suggesting more mature market positioning or conservative market share expansion relative to faster-growing IT peers. The company's Rule of 40 metric, combining growth and profitability, would approximate 30.6% (6.0% growth + 24.6% EBITDA margin estimate), exceeding the industry median of 20% and indicating balanced performance. Asset turnover of 0.60 aligns closely with the industry median of 0.67, reflecting similar capital intensity in software-driven business models. Accounts receivable days of approximately 155 days significantly exceed the industry median of 61 days, representing an area for improvement in working capital management relative to sector peers.

(Industry: IT and Telecom, Comparison: FY2025 Q3, Source: Proprietary analysis)

Key Takeaways from Earnings

The company demonstrates exceptional profitability characteristics with operating margin of 22.6% and ROE of 21.7% that place it in the top tier of healthcare IT solution providers, driven by a high-margin software and service business model with 57.0% gross margins. This structural profitability advantage has enabled accelerated earnings growth of 36.9% significantly outpacing revenue growth of 6.0%, reflecting operating leverage from the scalable platform. The balance sheet transformation is notable, with cash increasing 59.2% to ¥33.5B while maintaining conservative leverage at 0.19 debt-to-equity, providing substantial financial flexibility for strategic initiatives including the ¥8.0B in new long-term borrowings that appear designated for growth investments. Capital allocation shows balanced approach with conservative 15.2% dividend payout ratio supplemented by meaningful share repurchases evident in the ¥4.3B treasury stock increase, retaining majority earnings for reinvestment in the ¥46.3B intangible asset base that represents the company's competitive moat. The working capital profile warrants attention with 155-day receivable collection cycles double the industry median of 61 days, though strong cash generation has absorbed this thus far. Full-year guidance implies conservative positioning with 82-84% progress rates through Q3, suggesting potential for upside revision or robust Q4 buffer, though the temporary tax benefit of approximately ¥1.4B boosting FY2026 net income may not recur. The single-segment focus on pharmacy and healthcare solutions provides clear strategic focus but concentrates exposure to Japanese healthcare sector dynamics and regulatory evolution.

---

This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.

---

AI Financial Analysis

Executive Summary

FY2026 Q3 performance was strong, with profit growth materially outpacing revenue growth and full-year earnings guidance already substantially covered. Revenue increased 6.0% YoY to ¥8.93bn. Operating income rose 29.5% YoY to ¥2.02bn, while ordinary income increased 30.8% to ¥2.01bn. Profit attributable to owners of parent rose 35.2% to ¥2.11bn, equivalent to EPS of ¥189.36. The operating margin expanded to 22.6% from 18.5% in the prior-year period, a 409bp improvement. Gross margin, however, declined to 57.0% from 59.4%, a 240bp compression. The gross-margin dilution was more than offset by SG&A expenses declining 11.0% YoY to ¥3.07bn, reducing the SG&A-to-sales ratio by approximately 656bp to 34.4%. This indicates very strong operating leverage, although the sustainability of an absolute decline in SG&A should be monitored as the company pursues growth. The net profit margin was 23.7%, supported by an effective tax rate of negative 6.9%, as income tax expense was a ¥138m benefit. The tax benefit lifted net income above pre-tax profit and is therefore a material contributor to the reported bottom-line margin. Financial returns remain high, with reported annualized ROE of 28.4%, well above the 15% benchmark for excellent profitability. Liquidity is sound, with a 210.5% current ratio, ¥3.35bn of cash, and cash coverage of short-term borrowings of 3.35x. The balance sheet nevertheless has meaningful software and other intangible-asset exposure, with intangibles representing 31.1% of total assets. Accounts receivable of ¥3.79bn correspond to a high 116-day DSO, making collections and working-capital discipline a central issue. Q3 cumulative progress against full-year guidance is ahead of the standard 75% run rate for operating income, ordinary income, and profit attributable to owners. Revenue progress is slightly below the standard Q3 run rate, implying that the company must maintain sales momentum in Q4 even though the profit forecast is conservatively positioned. The proposed full-year DPS of ¥36 implies a payout ratio of approximately 15.2% against forecast EPS of ¥236.79, leaving considerable earnings retention capacity. Overall, the earnings trajectory is favorable, but investors should distinguish durable efficiency gains from the tax benefit and closely track receivable collection, intangible-asset productivity, and refinancing of short-term debt.

Profitability Analysis

The reported annualized DuPont ROE of 28.4% is decomposed into a 23.7% net profit margin, 0.800x asset turnover, and 1.50x financial leverage. Profitability rather than balance-sheet leverage is the principal driver of the high ROE: leverage is moderate and debt-to-equity is only 0.50x. The operating margin improved by 409bp YoY to 22.6%, despite a 240bp decline in gross margin to 57.0%. The largest positive operating change was SG&A leverage, as SG&A fell to ¥3.07bn from ¥3.45bn despite revenue growth of 6.0%; the SG&A ratio declined to 34.4% from 40.9%. As a result, operating income grew nearly five times faster than revenue. This is a favorable earnings-mix and cost-control outcome, but recurring earnings quality depends on whether lower SG&A reflects structural process efficiency rather than deferred sales, development, or personnel spending. Ordinary income of ¥2.01bn was broadly aligned with operating income, as net non-operating expense was limited to roughly ¥4m. Interest coverage was exceptionally strong at 330.6x, showing that financing costs currently have no material drag on earnings. The five-factor DuPont tax burden was 1.050 because tax expense was negative, which amplified reported net income. Accordingly, the 23.7% net margin and 28.4% annualized ROE should not be extrapolated without adjusting for the period's tax benefit. The asset-turnover component of 0.800x is reasonable for a digital healthcare-solutions company with a large software and intangible-asset base, but it remains the main structural constraint relative to the very high margin profile.

Growth Assessment

Revenue reached ¥8.93bn, up 6.0% YoY, demonstrating continued expansion in the pharmacy, medical, and nursing-care solutions business. The group operates as a single segment, making consolidated sales growth the relevant measure of business momentum. Operating income growth of 29.5% and ordinary income growth of 30.8% substantially exceeded sales growth, confirming strong operating leverage during the period. The full-year plan calls for revenue of ¥12.30bn, up 9.8% YoY, operating income of ¥2.45bn, up 25.4%, and ordinary income of ¥2.40bn, up 23.7%. Cumulative Q3 revenue represents 72.6% of the full-year revenue forecast, 2.4 percentage points below the standard 75% Q3 progress rate. In contrast, operating income has reached 82.2% of the annual plan, 7.2 percentage points ahead of the standard run rate, while ordinary income has reached 83.8%, 8.8 percentage points ahead. Profit attributable to owners has reached 78.5% of the ¥2.69bn forecast, 3.5 percentage points ahead of the standard run rate. This pattern indicates that guidance assumes a lower Q4 operating margin than achieved cumulatively through Q3, or retains an appropriately conservative allowance for Q4 costs. To achieve the revenue plan, Q4 sales need to be approximately ¥3.37bn, compared with cumulative quarterly average revenue of roughly ¥2.98bn. The core growth question is whether the company can sustain sales growth while preserving the sharply lower SG&A ratio and converting a large receivables balance into cash. The substantial software asset base of ¥3.91bn also makes ongoing monetization and utilization of internally developed or acquired digital platforms important to long-term growth quality.

Financial Health

Financial health is sound on reported liquidity and leverage measures. Current assets of ¥7.91bn exceeded current liabilities of ¥3.76bn, producing a current ratio and quick ratio of 210.5%. Working capital was ¥4.15bn, providing a sizable liquidity buffer. Cash and deposits increased ¥1.25bn YoY to ¥3.35bn, equivalent to 22.5% of total assets. Interest-bearing debt totaled ¥1.86bn, consisting of ¥1.00bn of short-term loans and ¥860m of long-term loans. Debt-to-equity was a conservative 0.50x and debt-to-capital was 15.8%, both well within investment-grade-style reference thresholds. Cash covered short-term loans by 3.35x, substantially mitigating near-term maturity mismatch risk. However, the 53.8% short-term debt ratio triggers a refinancing-risk alert because more than half of borrowings mature within one year. The risk is presently manageable given cash balances and current assets, but refinancing terms and the intended use of incremental borrowing should be monitored. Long-term loans increased by ¥796m YoY to ¥860m, indicating a material increase in longer-dated funding alongside balance-sheet expansion. Total equity rose ¥1.40bn YoY to ¥9.91bn, primarily supported by retained earnings, strengthening loss-absorption capacity. Treasury stock increased to ¥428m, or 2.9% of total assets, reflecting capital deployment that reduces reported equity but remains modest relative to the company's capital base. Intangible assets were ¥4.63bn, or 31.1% of total assets, above the 30% concentration threshold; this makes asset value and future profitability more dependent on sustained returns from software and other digital assets. Goodwill was limited at ¥449m, only 4.5% of equity and 3.0% of assets, so goodwill impairment risk is comparatively contained.

Notable B/S Changes

Cash and deposits: +¥1.25bn (+59.2%) to ¥3.35bn - materially strengthens liquidity and provides substantial coverage for ¥1.00bn of short-term loans. Long-term loans: +¥796m (+1,248.6%) to ¥860m - indicates a notable expansion of longer-term funding; leverage remains moderate but deployment returns should be monitored. Retained earnings: +¥1.81bn (+47.0%) to ¥5.66bn - reflects strong profit retention and materially reinforces the equity buffer. Treasury stock: increased by ¥428m to negative ¥428m - represents meaningful capital deployment, equal to 2.9% of total assets, while remaining manageable relative to total equity. Investments and other assets: +¥927m (+72.2%) to ¥2.21bn - a sizable increase within noncurrent assets that should be evaluated for strategic purpose and return generation. Total assets: +¥2.73bn (+22.5%) to ¥14.89bn - growth was funded by higher equity, increased long-term borrowings, and expanded liabilities, while capital adequacy remained solid at 65.9%.

Cash Flow Quality

Reported earnings quality is supported by strong operating profitability, but cash conversion requires close monitoring because trade receivables were ¥3.79bn and DSO was high at 116 days. A 116-day DSO is materially above the 60-day alert threshold and indicates that a significant share of sales remains uncollected at period-end. Receivables increased 7.5% YoY, broadly in line with revenue growth, but the absolute receivables balance equals 42.4% of cumulative Q3 revenue. This creates sensitivity to customer payment timing, billing cycles, credit terms, and any deterioration in collection performance. The company's ¥3.35bn cash balance provides a meaningful buffer against this working-capital exposure. The negative income tax expense of ¥138m also means reported net income of ¥2.11bn exceeds pre-tax profit of ¥2.01bn; this is a tax-related uplift rather than a direct indicator of recurring cash generation. Software represented ¥3.91bn, or 26.3% of total assets, underscoring the importance of disciplined capitalization policies and subsequent amortization or impairment testing. The low goodwill-to-equity ratio reduces acquisition-accounting risk, but the broader intangible concentration makes cash returns on product development and platform investments central to earnings durability.

Dividend Sustainability

The company has forecast FY2026 DPS of ¥36.00. Based on forecast EPS of ¥236.79, the dividend payout ratio is approximately 15.2%, well below the 60% sustainability benchmark. The low payout ratio leaves substantial capacity to retain earnings for organic growth, debt management, and potential capital returns. Cumulative Q3 EPS of ¥189.36 already represents 80.0% of full-year forecast EPS, which supports the affordability of the indicated dividend under the present earnings outlook. The Q2 dividend was ¥0, consistent with a year-end-oriented distribution profile. Retained earnings increased ¥1.81bn YoY to ¥5.66bn, further supporting the equity base behind shareholder distributions. Treasury stock of ¥428m indicates that capital allocation has also included repurchases or equivalent treasury-share acquisition activity; dividends and buybacks should be assessed together as a total return ratio when the size of period buybacks is available. The principal factors affecting dividend durability are the sustainability of the elevated operating margin, collection of trade receivables, and preservation of cash after debt servicing and software-related investment.

Risk Assessment

Business risks include Receivables and collection risk is elevated: trade receivables were ¥3.79bn and DSO was 116 days, well above the 60-day alert level. Delayed reimbursement or payment cycles among pharmacy, medical, and care-sector customers could pressure cash conversion., Digital healthcare and pharmacy-solution providers face industry-specific risks from changes in healthcare reimbursement, pharmacy regulation, electronic prescription standards, personal-data protection requirements, and customer IT budgets., The 240bp decline in gross margin indicates that pricing, customer mix, or service-delivery costs should be monitored even though SG&A leverage drove a higher operating margin., The company has a concentrated operating model as a single pharmacy, medical, and nursing-care solutions segment, increasing exposure to sector-wide demand or regulatory changes..

Financial risks include Short-term loans account for 53.8% of interest-bearing debt, exceeding the 40% alert threshold. Liquidity is currently strong, but refinancing timing and lending conditions remain relevant., Intangible assets account for 31.1% of total assets, above the 30% concentration alert threshold. Lower-than-expected monetization of software and other intangible assets could result in future amortization burdens or impairment risk., Long-term loans increased ¥796m YoY to ¥860m. Although leverage remains conservative, the increase warrants assessment against the return generated by funded investments., The effective tax rate was negative 6.9%, and the tax burden exceeded 1.0x. A normalization of tax expense could reduce future net-margin and ROE comparability..

Key concerns include Highest priority: whether the 116-day DSO converts into timely cash receipts without credit losses or a further rise in working-capital needs., High priority: whether the sharp SG&A ratio improvement is structurally sustainable while the company continues to target 9.8% full-year revenue growth., Moderate priority: recurring earnings should be evaluated separately from the period's ¥138m income-tax benefit., Moderate priority: returns generated from the ¥4.63bn intangible-asset base, particularly ¥3.91bn of software, should remain sufficient to avoid impairment or weak asset turnover..

Investment Implications

Key takeaways include Operating performance is strong: revenue grew 6.0% YoY while operating income grew 29.5%, lifting the operating margin by 409bp to 22.6%., Reported annualized ROE of 28.4% is excellent and is driven primarily by high profitability rather than aggressive leverage., Q3 cumulative operating-income progress of 82.2% is ahead of the 75% seasonal benchmark, whereas revenue progress of 72.6% requires a stronger Q4 sales contribution., The balance sheet is liquid and conservatively leveraged, with a 210.5% current ratio, 0.50x debt-to-equity, and ¥3.35bn of cash., High DSO and intangible-asset concentration are the main balance-sheet issues requiring ongoing diligence..

Metrics to watch include Revenue growth and Q4 revenue required to meet the ¥12.30bn full-year forecast, Operating margin and SG&A-to-sales ratio, to test the durability of operating leverage, Trade receivables, DSO, and collection trends, Short-term debt refinancing, cash-to-short-term-debt coverage, and total interest-bearing debt, Software and total intangible assets as a percentage of assets, together with any amortization or impairment charges, Effective tax rate and the extent to which net income remains supported by tax benefits, Full-year DPS of ¥36 and dividend payout ratio relative to realized EPS.

Regarding relative positioning, The company presents an asset-light operating profile in physical fixed assets but a software- and intangible-intensive digital-solutions profile. Its 22.6% operating margin, 23.7% net margin, and 28.4% annualized ROE are well above the supplied profitability benchmarks, while leverage is conservative. Relative strength is therefore concentrated in margins, returns, and liquidity; relative vulnerabilities are slower receivable conversion and a balance sheet whose earning capacity depends materially on intangible-asset productivity.